Latest Expert Opinions

Signal
Opinion
Expert
BUY
BUY
January 13, 2021
They make drugs for pets and livestock. Under the new CEO, ZTS is up 22% despite taking a beating during last year's lockdown. ZTS has since delivered a couple of strong quarters.
Show full opinionHide full opinion
Zoetis Inc (ZTS-N)
January 13, 2021
They make drugs for pets and livestock. Under the new CEO, ZTS is up 22% despite taking a beating during last year's lockdown. ZTS has since delivered a couple of strong quarters.
BUY
BUY
January 13, 2021
Developing drugs for MS and blood cancers like leukemia. Exciting prospects; boasts promising clinical trial results, especially for their MS drug. Last month, they announced good phase 3 results for that drug which lifted share from the $30's to $50's. Cash flow is fine; they just said they've raised a lot of money.
Show full opinionHide full opinion
TG Therapeutics (TGTX-Q)
January 13, 2021
Developing drugs for MS and blood cancers like leukemia. Exciting prospects; boasts promising clinical trial results, especially for their MS drug. Last month, they announced good phase 3 results for that drug which lifted share from the $30's to $50's. Cash flow is fine; they just said they've raised a lot of money.
PARTIAL SELL
PARTIAL SELL
January 13, 2021
Sell after entering last March? Shares have since soared. Sell a third, then let the rest run.
Show full opinionHide full opinion
Halliburton Co (HAL-N)
January 13, 2021
Sell after entering last March? Shares have since soared. Sell a third, then let the rest run.
BUY
BUY
January 13, 2021
Pays a 3% dividend and offers a good balance sheet. Be patient. It'll take time to turn around the ship. In fact, you can buy more now.
Show full opinionHide full opinion
Cisco (CSCO-Q)
January 13, 2021
Pays a 3% dividend and offers a good balance sheet. Be patient. It'll take time to turn around the ship. In fact, you can buy more now.
DON'T BUY
DON'T BUY
January 13, 2021
Has a poor balance sheet, but the sector is rising. ET-N is the weakest in this space given that balance sheet.
Show full opinionHide full opinion
Energy Transfer LP (ET-N)
January 13, 2021
Has a poor balance sheet, but the sector is rising. ET-N is the weakest in this space given that balance sheet.
BUY
BUY
January 13, 2021

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. It should be considered higher risk income, but it has a long history. Management is decent. It has survived many downturns and has managed to grow. Unlock Premium - Try 5i Free

Show full opinionHide full opinion
Alaris Royalty (AD-T)
January 13, 2021

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. It should be considered higher risk income, but it has a long history. Management is decent. It has survived many downturns and has managed to grow. Unlock Premium - Try 5i Free

BUY WEAKNESS
BUY WEAKNESS
January 13, 2021

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. The sell off today is probably over done. If the deal doesn’t go through, which is highly probable, the stock should bounce back. If it goes through, management has executed well in the past so it should be okay. Unlock Premium - Try 5i Free

Show full opinionHide full opinion

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. The sell off today is probably over done. If the deal doesn’t go through, which is highly probable, the stock should bounce back. If it goes through, management has executed well in the past so it should be okay. Unlock Premium - Try 5i Free